{"id":"31442479070-19","name":"SFL Regulatory Affairs &amp; Scientific Communication GmbH","registrationDate":"2012-07-02T14:04:35.045+02:00","category":1,"subCategory":6,"legal":"GmbH (Ltd liab. Co.)","web":"http://www.sfl-services.com","country":"Switzerland","headAddress":"Schillerstrasse 7","headCity":"Basel","headPostCode":"4053","headPhone":"(41)6 13 61 94 43","boss":"Shayesteh Fürst-Ladani","bossTitle":"Ms","bossPosition":"CEO","membersCount":4,"membersFTE":"2.0","membership":"SFL is an associate member of EuropaBio &#xd;\n&#xd;\nSFL is a member of SWISS MEDTECH&#xd;\n&#xd;\nSFL is a member of the British-Swiss Chamber of Commerce&#xd;\n&#xd;\nSFL is a member of Rare Disease Action Forum (RDAF)&#xd;\n&#xd;\nSFL is a member of Medtech &amp; Pharma Platform (MPP)","memberOrga":"","goal":"SFL Regulatory Affairs &amp; Scientific Communication Ltd (SFL) is a multi-national team with extensive experience in the pharmaceutical as well as medtech industries.&#xd;<br />&#xd;<br />SFL’s core competencies are: &#xd;<br />•  Regulatory Affairs &#xd;<br />•  Public Affairs and Market Access&#xd;<br />•  Legal Advice&#xd;<br />•  Medical Affairs&#xd;<br />&#xd;<br />&#xd;<br />This enables us to understand and meet clients’ needs through every stage of the product lifecycle. Each team member has a proven track record in specific areas of expertise and an excellent understanding of the interconnectedness of the different stages and functions of the lifecycle of a product. &#xd;<br />&#xd;<br />Public Affairs Services&#xd;<br />SFL advises organizations on how to engage in the EU debate to shape healthcare policies and regulatory frameworks. Our team has extensive hands-on experience and proven success in contributing to EU healthcare laws and policies. SFL's public affairs team has worked in functions inside the industry as well as in the public sector. Our public affairs services comprise:&#xd;<br />EU political intelligence (monitoring, impact analysis of coming/changing laws and policies, news updates tailored to client needs)&#xd;<br />Engagement strategy (stakeholder mapping, strategic partnerships, working with industry associations, step-by-step plans to address policy and regulatory matters, support with drafting communication materials, coordination of workshops and debates)&#xd;<br />Capacity building (training on Eu institutions and legislative processes, public affairs methods and tools, lobbying codes, advice on internal organizational matters to help clients formulate aligned positions and speak with one voice to regulators and policy-makers)&#xd;<br />&#xd;<br />SFL supports our clients by offering personalized and comprehensive services which, when combined, provide an integrated solution for products from the bench to the marketplace within one consultancy. &#xd;<br />SFL offers expertise in the following product classes - drugs, medical devices, in vitro diagnostics, combination products, and ATMPs - and in a broad range of therapeutic areas.&#xd;<br />&#xd;<br />SFL is an associate member of EuropaBio, and board member of the Rare Disease Action Forum (RDAF) and Medtech &amp; Pharma Platform (MPP).","acronym":"SFL","interests":"Business and Industry, Communication, Competition, Consumers, Digital economy and society, External Relations, Food Safety, General and Institutional Affairs, Public Health, Research and innovation, Single market, Trade","euInitiatives":"Proposal for a Regulation on Health Technology Assessment - 2018/018 (COD)&#xd;<br />Medical Devices Regulation -  EU No 2017/745&#xd;<br />In-vitro Diagnostics Regulation - EU No 2017/746&#xd;<br />Clinical Trials Regulation - EU No 536/2014&#xd;<br />Data Protection Regulation - EU No 2016/679&#xd;<br />EUnetHTA&#xd;<br />European Medicines Agency policy on publication of&#xd;<br />clinical data for medicinal products for human use - EMA/240810/2013&#xd;<br />Horizon 2020&#xd;<br />EU pharmacovigilance system including Regulation No 1235/2010 and Directive 2010/84/EU as integrated in Regulation (EC) No 726/2004 and Directive 2001/83/EC &#xd;<br />EU personalised medicine activities such as Use of '-omics' technologies in the development of personalised medicine SWD(2013) 436 final &#xd;<br />Orphan Drug Regulation - EU No 141/2000","lastUp":"2018-04-24T18:23:55.971+02:00","customers":"F. Hoffmann-La Roche Ltd","costAbsolu":"","costRange":"100000-199999","turnoverAbsolu":"","turnoverRange":"100000-499999"}